Citations

Clear

1011 citation(s) found for "Barry, WT".

Incremental Prognostic Power of Coronary Flow Reserve and Artificial Intelligence–Enabled ECG–Derived Filling Pressure in Angina With Nonobstructive Coronary Arteries
Kalhor, Parvin , Manzato, Matteo , Hellou, Elias, Nardi, Valentina , Borlaug, Barry A. , Lerman, L. O., Lerman, Amir , Hellou, Elias , Hellou, Elias , Nogami, Kai , Nardi, Valentina , Borlaug, Barry A , Lerman, Lilach O , Lerman, Amir , Manzato, Matteo , Lerman, Lilach O.

Mayo Clinic

Journal of the American Heart Association | May 6, 2026 | Volume: 15 | Issue: 10 | Pages: No page available

10.1161/jaha.125.047946 | PMID 42089212 Get It

Background Coronary flow reserve reflects microvascular function, whereas filling pressure indicates myocardial hemodynamic burden. In angina with nonobstructive coronary arteries, abnormalities in either could contribute to a supply–demand mismatch; however, their combined prognostic significance remains unclear. Methods Patients with angina with nonobstructive coronary arteries who underwent invasive coronary reactivity tests were studied retrospectively. Coronary microvascular dysfunction (CMD) was coronary flow reserve <2.5. An artificial intelligence–enabled ECG marker of elevated filling pressure (AIEFP) was applied as a scalable prognostic marker of myocardial hemodynamic stress. Associations with major adverse cardiovascular events were evaluated using Cox regression and propensity score overlap weighting. Results Among 1957 patients with angina with nonobstructive coronary arteries (median age, 51.8 years; 67.2% women), CMD+ was identified in 26.4% and AIEFP+ in 6.6%. Over 8 years, 204 patients (10.4%) experienced major adverse cardiovascular events. In nested models, both CMD (hazard ratio [HR]=1.42 [95% CI=1.13–1.78]; P =0.002) and AIEFP (HR=2.28 [95% CI=1.67–3.11]; P <0.001) remained associated with major adverse cardiovascular events after adjustment. Adding AIEFP to the base model improved model fitness (Δχ 2 =23.65, P <0.001; ΔAkaike Information Criterion=−21.7) and modestly improved discrimination (ΔHarrell concordance index=0.02, P =0.02). In a 4‐group model, adjusted risks increased in a graded manner. Overlap‐weighted analysis after covariate balance demonstrated distinct temporal risk trajectories: CMD+/AIEFP+ had the highest 1‐year risk (12.7%), and AIEFP+ had the highest cumulative 8‐year risk (57% in CMD− and 51.8% in CMD+). Conclusions CMD and AIEFP provide complementary prognostic information, with AIEFP remaining significantly associated with outcomes after multivariable adjustment. A dual‐axis framework integrating myocardial hemodynamic stress (AIEFP) and microvascular function (coronary flow reserve) may enhance risk stratification and enable identification of clinically distinct angina with nonobstructive coronary arteries phenotypes with divergent trajectories.
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
Mendieta, Guiomar , Ridker, Paul M. , Borlaug, Barry A. , Ducharme, Anique , Lam, C S P, Voors, Adriaan A, Auerbach, Pernille, Cikes, Maja, Fudim, Marat, Hvelplund, Anders, Lam, Carolyn S.P. , Lam, Carolyn S P , Petrie, Mark C , Ridker, Paul M. , Borlaug, Barry A , Ducharme, Anique , Voors, Adriaan A. , Auerbach, Pernille, Čikeš, Maja , Fudim, Marat , Michelsen, Marie Mide , Petrie, Mark C.

Mayo Clinic

European Journal of Heart Failure | May 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag153 | PMID 42106986 Get It

Abstract Aims We hypothesized that targeting interleukin-6—a cytokine central to NOD-like receptor protein 3 (NLRP3) inflammasome activation that is associated with both the onset and progression of heart failure (HF)—may be beneficial in patients with HF and circulating evidence of cardiovascular inflammation but without overtly reduced ejection fraction (EF). We describe the rationale and design of two clinical trials (ATHENA and HERMES) investigating ziltivekimab, a human monoclonal antibody directed against the interleukin-6 ligand, in patients with HF and mildly reduced or preserved EF (HFmrEF/HFpEF) and cardiovascular inflammation. Methods ATHENA (n = 673) and HERMES (n = 4900) are international, multi-centre, double-blind, placebo-controlled trials randomizing adults with HFpEF/HFmrEF and cardiovascular inflammation (high-sensitivity C-reactive protein ≥2 mg/l) to ziltivekimab 15 mg or placebo, administered subcutaneously once monthly on top of standard of care. Eligible participants have a left ventricular EF &gt;40%, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), and serum high-sensitivity C-reactive protein ≥2 mg/l. The primary endpoint in ATHENA is the change in Kansas City Cardiomyopathy Questionnaire—Clinical Summary Score at 12 months. The primary endpoint in HERMES is time to first composite of cardiovascular death, hospitalization for HF, or urgent HF visit. ATHENA has a fixed duration of 12 months, whereas the HERMES trial is event driven (∼845 adjudicated primary events) with a minimum exposure of 6 months from randomization to the last treatment visit. Conclusion ATHENA and HERMES will investigate the effect of ziltivekimab in HFpEF/HFmrEF and cardiovascular inflammation. ATHENA will determine the effect of ziltivekimab on health status. HERMES will determine the efficacy and safety of ziltivekimab on morbidity and mortality.
Abstract MPTH62: Midlife Resistance Exercise Behaviors and Incident Heart Failure with Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study
McDonough, DJ, Avenido, Francis Ryan, Demmer, Ryan, Gabriel, Kelley, VanWagner, Lisa, Borlaug, Barry, Stovitz, Steven, Meyer, Markus, Erickson, Darin, Palta, Priya, Pereira, Mark, Demmer, Ryan T. , Gabriel, Kelley Pettee , VanWagner, Lisa B , Stovitz, Steven D. , Meyer, Markus

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.mpth62 Get It

Introduction: Heart failure (HF) with preserved ejection fraction (HFpEF) is now the predominant HF subtype, largely driven by the syndemic of physical inactivity and overweight/obesity in an aging population. Deranged skeletal muscle energetics and regional ectopic adipose depots are key cardiometabolic pathways in the pathogenesis of HFpEF, both of which may be favorably modified by 1-2 hours/week of resistance exercise (RE). However, its association with HFpEF risk has not been thoroughly examined. We investigated the association between midlife RE behaviors and incident HFpEF in the Atherosclerosis Risk in Communities (ARIC) study. Hypothesis: Participation in RE at midlife is inversely associated with the risk of incident HFpEF. Methods: Our exposure (RE)—including weightlifting and bodyweight resistance exercises—was assessed using the validated Baecke questionnaire and reported weekly RE duration was averaged across Visits 1 and 3 (1987-1995). We dichotomized averaged RE as 0 hr/wk (‘No RE’, reference) and >0 hr/wk (‘Any RE’). Our outcome (incident HFpEF) was identified through committee-adjudicated HF hospitalizations (January 1, 2005 to December 31, 2023) using medical chart abstraction. Participants with prevalent HF, death, or loss to follow-up before January 1, 2005 were excluded. We constructed Cox regression models to evaluate the association between midlife RE and incident HFpEF. Model 1 adjusted for age, sex, race, field center, education, smoking status, alcohol consumption, and non-RE physical activity. Given that adiposity may lie on the causal pathway, waist-height ratio (WHtR; both measured in cm) was added in Model 2. Results: 10,751 Black and White participants (803 incident HFpEF cases) were analyzed over a median follow-up time of 14.4 years (mean±SD Visit 1 age, 53.3±5.6 years; average Visit 1 and 3 WHtR, 0.58±0.08; 24.7% Black; 57.4% female). 1,217 participants (11.3%) reported engaging in RE at Visits 1 and/or 3, with a median duration of 0.84 hr/wk (IQR, 0.50-1.61). Compared to No RE, the fully adjusted hazard ratio (HR) for Model 1 for Any RE was: 0.78 (95% CI, 0.61-1.00, P = 0.05). The association was attenuated after adjustment for WHtR: HR = 0.84 (0.65-1.07, P = 0.16). Conclusion: Participation in RE at midlife is associated with a 22% lower risk of incident HFpEF. To inform public health and clinical guidelines, further studies are needed to clarify the role of RE in HFpEF prevention.
Kidney dysfunction and pulmonary vascular disease in heart failure with preserved ejection fraction
Amdahl, Matthew B. , Naser, Jwan A. , Tada, Atsushi , Doi, Shunichi, Harada, Tomonari , Ibe, Tatsuro , Testani, Jeffrey M, Melenovský, Vojtěch , Reddy, Yogesh N V, Borlaug, Barry A. , Borlaug, Barry A , Melenovský, Vojtěch , Naser, Jwan A , Doi, Shunichi, Testani, Jeffrey M. , Reddy, Yogesh N.V.

Mayo Clinic

European Journal of Heart Failure | April 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag140 | PMID 42044030 Get It

Abstract Aims Chronic kidney disease (CKD) is common in patients with heart failure (HF) with preserved ejection fraction (HFpEF), and its presence is associated with more severe echocardiographic abnormalities and poorer outcomes through unclear mechanisms. CKD-associated endothelial dysfunction, inflammation, and activation of profibrotic pathways could worsen pulmonary vascular disease (PVD) in HFpEF, but such relationships have not been explored. Methods Consecutively evaluated patients with HFpEF undergoing invasive haemodynamic cardiopulmonary exercise testing were stratified by baseline kidney function to characterize potential differences in pulmonary vascular loading, haemodynamics, cardiopulmonary reserve, and outcomes based upon the presence and severity of kidney dysfunction. Results Of 925 patients with HFpEF, 319 (34.5%) had estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73 m2. Patients with more severe kidney dysfunction were older and more likely to have diabetes, atrial fibrillation, and hypertension. At rest, reduced kidney function was associated with lower haemoglobin, higher biventricular filling pressures, and lower cardiac output, but the severity of kidney dysfunction was most conspicuously associated with worsening PVD, evidenced by increasing pulmonary arterial (PA) pressures due to marked increases in pulmonary vascular resistance (PVR) as kidney dysfunction progressed (median [IQR] 1.3 [0.86, 1.88] to 2.8 [2.0, 3.8] WU from eGFR ≥ 90 to eGFR &lt; 30, P &lt; .001), along with progressively lower PA compliance (PAC, 4.7 [3.6, 5.8] to 2.2 [1.8, 3.4] ml/mmHg from eGFR ≥ 90 to eGFR &lt; 30, P &lt; .001). With exercise, differences in the severity of PVD became even more striking, with more severe elevation in PA pressures and PVR, and lower PA compliance, leading to lower transmural left-sided distending pressures, with no difference in exertional PA wedge pressure. Patients with worse kidney dysfunction displayed the most dramatic cardiac output limitations with exercise, which along with more severe anaemia and markedly reduced O2 delivery, caused marked impairment in aerobic capacity. Worsening kidney function was associated with a striking gradient of increased risk of a composite of all-cause death and HF hospitalization [ranging from HR 2.38 (95% CI 1.01–5.59) for eGFR 60–90 to HR 16.77 (95% CI 6.65–42.28) for eGFR &lt; 30 (vs. reference eGFR ≥ 90)]. Conclusions Kidney dysfunction in patients with HFpEF is characterized by more severe PVD at rest and with exercise, leading to reduced cardiac output reserve, impaired exercise capacity, and increased risk for adverse events. Further study is warranted to better understand causal relationships between CKD and PVD, and determine whether novel therapies to improve kidney function might target these impairments to improve clinical status.
Evaluation of standard and modified two-tiered testing algorithms using well-characterized early Lyme disease samples
Horn, Elizabeth J. , Menefee, Barry, Schotthoefer, Anna M. , Dempsey, George, McArdle, Matt, Weber, A., Luca, Cathy De, Pritt, Bobbi S. , Branda, John A. , Horn, Elizabeth J , Weber, Allison F , Pritt, Bobbi S , Dempsey, George, McArdle, Matthew

Mayo Clinic

Journal of Clinical Microbiology | April 21, 2026 | Volume: 64 | Issue: 5 | Pages: No page available

10.1128/jcm.01187-25 | PMID 42012197 Get It

ABSTRACT Current laboratory testing for Lyme disease (LD) relies on serology. We evaluated the performance of standard two-tiered testing (STTT) and modified two-tiered testing (MTTT) algorithms using samples obtained from well-characterized patients with early LD in the U.S. East Coast and Upper Midwest. Participants with signs and symptoms of early LD (cases) and controls were enrolled by Lyme Disease Biobank. We compared the performance of four FDA-cleared STTT or MTTT algorithms using serum samples from 251 participants (107 cases, 69 with a convalescent draw; 144 endemic controls). At the initial blood draw, algorithm sensitivity ranged from 22% to 36%, with specificity ranging from 98% to 100%. MTTT algorithms showed higher sensitivity compared with STTT algorithms ( P ≤ 0.05). One STTT algorithm was less sensitive than the other ( P = 0.035), and there was no significant difference in sensitivity between MTTT algorithms. There was also discordance between algorithms; only 22 of the 45 samples classified as laboratory confirmed by Lyme Disease Biobank testing were positive using all algorithms evaluated. Likelihood of positive two-tiered serology among cases with a suspected erythema migrans (EM) skin lesion increased with longer lesion duration and/or when presenting with >1 constitutional symptom. Participants with suspected EM without constitutional symptoms were unlikely to test positive by any algorithm evaluated. Testing convalescent samples did not improve LD detection, and seroconversion was rare. While MTTT confirmed more early LD cases than STTT, all two-tiered algorithms evaluated were insensitive in this population. Novel diagnostics that improve laboratory confirmation for early LD are urgently needed. IMPORTANCE This study confirms that two-tiered serologic testing algorithms are insensitive in early Lyme disease, particularly within the first 2 weeks after symptom onset or when erythema migrans is not accompanied by constitutional symptoms. It also demonstrates that seroconversion is rare after antibiotic treatment. These results highlight the need for novel diagnostics for early Lyme disease that do not rely on serologic testing.
Metabolomics of Right Ventricular Function in Pulmonary Hypertension
Chacon-Barahona, Jonathan , Chung, Samuel J. , Garry, Jonah , Frantz, Robert P. , Hassoun, Paul M. , Mathai, Stephen C. , Simpson, Catherine E. , Beck, Gerald, Hill, Nicholas S. , MUKHERJEE, MONICA, Jacob, Miriam , Park, M H, Finet, J Emanuel, Farha, Samar , Grünig, Gabriele , Kwon, Deborah, Comhair, Suzy , Erzurum, Serpil, Barnard, John, Jellis, Christine , Racanelli, Alexandra Christin, Krumsiek, Jan , hemnes, anna, Horn, Evelyn, Group, on behalf of the PVDOMICS Study, Beck, Gerald J. , Garry, Jonah D , Hassoun, Paul M , Mathai, Stephen C , Simpson, Catherine E , Beck, Gerald J , Hill, Nicholas S , Leopold, Jane A , Waxman, Aaron B. , Rosenzweig, Erika B , Borlaug, Barry A , Mukherjee, Monica , Vanderpool, Rebecca R , Jacob, Miriam , Mehra, Reena , Park, Margaret M , Finet, J Emanuel , Kwon, Deborah H , Comhair, Suzy , Erzurum, Serpil C , Barnard, John , Hu, Bo , Jellis, Christine L , Krumsiek, Jan , Brittain, Evan L , Hemnes, Anna , Horn, Evelyn M , Frantz, Robert P , Chacon-Barahona, Jonathan , Chung, Samuel J. , Rischard, Franz , Leopold, Jane A. , Rosenzweig, Erika B. , Borlaug, Barry A. , Mukherjee, Monica , Vanderpool, Rebecca , Mehra, Reena , Finet, J. Emanuel , Erzurum, Serpil C. , Racanelli, Alexandra C. , Hemnes, Anna R. , Gro, on behalf of the PVDOMICS Study

Mayo Clinic

Circulation Research | April 15, 2026 | Volume: 138 | Issue: 11 | Pages: No page available

10.1161/circresaha.125.327342 | PMID 41983297 Get It

BACKGROUND: The metabolic mechanisms underlying right ventricular (RV) dysfunction are poorly understood, particularly outside of group 1 pulmonary hypertension (PH). We aimed to identify metabolites and pathways associated with RV systolic function and explored whether associations differed by pulmonary vascular resistance, PH group 1 status, and sex. METHODS: We analyzed data from the multicenter PVDOMICS (Pulmonary Vascular Disease Phenomics) cohort. RV systolic function metrics included fractional area change (echo), global longitudinal strain (echo), and ejection fraction (cardiac magnetic resonance). We used linear regression adjusted for age, sex, body mass index, and PH group to assess associations between metabolites and RV function. Pathway enrichment analyses were used to identify pathways significantly associated with RV function. Interaction terms were assessed to determine whether metabolite associations were modified by pulmonary vascular resistance, group 1 PH status, or sex. Least absolute shrinkage and selection operator regression was used to develop metabolite-based scores for RV function, and prognostic performance was assessed. RESULTS: There were 979 participants with plasma metabolomics and RV function data. Linear regression identified 170 metabolites that were significantly associated with all 3 RV metrics. Androgenic steroid, gamma-glutamyl amino acid, polyamine, vitamin A, fatty acid, and sterol pathways are most strongly associated with RV systolic function. Two metabolites interacted with group 1 PH status, and 6 interacted with pulmonary vascular resistance. Four androgenic steroids are associated more strongly with RV systolic function in women compared with men. Metabolite-based scores were prognostically equivalent to RV systolic function metrics and less accurate than REVEAL Lite 2 scores. CONCLUSIONS: We provide a blueprint of metabolites and metabolic pathways associated with RV systolic function across the spectrum of PH. Novel links to vitamin A and glutathione metabolites were observed. We detected few metabolites that associated with RV systolic function differentially by group 1 PH status or degree of pulmonary vascular resistance elevation. Androgenic steroids may associate more strongly with RV systolic function in women compared with men.
Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America—A 5‐Year Analysis
Martins, Adrielly , Reddy, A. Nagarjuna, Dean, Richard, Gordon, Stuart C. , Pratt, Daniel, Li, Michael, Forman, Lisa , Lammert, Craig , Yiman, Kidist, Gallegos‐Orozco, Juan F. , Carey, Elizabeth J. , Lytvyak, Ellina , Goldberg, David S. , Naugler, Scott, Yu, Lei, Assis, David N. , Bowlus, Christopher L., Bowlus, Christopher L. , Bonder, Alan , Schlansky, Barry L , Montano-Loza, Aldo J , Lytvyak, Ellina , Goldberg, David , Assis, David N , Levy, Cynthia , Bowlus, Christopher L , Reddy, Anish , Dean, Richard , Li, Michael, Montaño‐Loza, Aldo J. , Levy, Cynthia

Mayo Clinic

Liver International | April 11, 2026 | Volume: 46 | Issue: 5 | Pages: No page available

10.1111/liv.70645 | PMID 41964270 Get It

ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease with a high risk of malignancy and limited therapeutic options. Both the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) recommend structured baseline evaluation, fibrosis staging and longitudinal surveillance. However, real‐world adherence to these practices in North America remains unclear. Methods We conducted a retrospective cohort study of 1300 patients with PSC enrolled in the Consortium for Autoimmune Liver Diseases (CALiD) registry between 2018 and 2024 across 19 centres in North America. Guideline adherence was assessed for diagnostic measures at baseline (colonoscopy to establish IBD status and noninvasive fibrosis staging) and longitudinal surveillance (colonoscopy in PSC‐IBD, abdominal imaging for hepatobiliary cancer surveillance and CA 19‐9 testing). Prescribing patterns for ursodeoxycholic acid (UDCA) were also characterised. Multivariable logistic regression was used to evaluate demographic, clinical and socioeconomic predictors of adherence. Results At diagnosis, 78.8% of eligible patients with available data underwent colonoscopy to establish IBD status, and 45% underwent noninvasive fibrosis staging. During follow‐up, only 30%–35% of patients with PSC‐IBD underwent colonoscopy annually, while abdominal imaging for hepatobiliary cancer surveillance declined from 74% at Year 1 to 51% by Year 4. CA 19‐9 testing was documented in 47% over 5‐year period. UDCA was prescribed in 51% at baseline, with median dose of 12.5 mg/kg/day. Socioeconomic factors, including lower education and household income, were associated with reduced adherence, while cirrhosis strongly predicted completion of surveillance imaging. Conclusions Adherence to guideline‐based care in PSC remains suboptimal in North America Suboptimal adherence was observed for strongly recommended practices with longstanding guideline support (colonoscopy to establish IBD status; annual CRC surveillance in PSC‐IBD) as well as practices where guideline consensus has evolved more recently or where societies differ (baseline fibrosis assessment; hepatobiliary cancer imaging). Efforts to standardise care and address socioeconomic barriers are urgently needed to improve outcomes.
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients
Waddington‐Cruz, Márcia , Berk, John L. , Parman, Yeşim , Gertz, Morie, Khella, Sami , Weiler, Markus , Kwoh, T. Jesse , Pola, Maksym , Reicher, Barry , Nåtman, Jonatan , Dasgupta, Noel R., Wixner, Jonas, Gertz, Morie A. , Gertz, Morie A , Nåtman, Jonatan , Dasgupta, Noel , Wixner, Jonas , Berk, John L , Waddington-Cruz, Márcia , Wixner, Jonas

Mayo Clinic

Muscle & Nerve | April 6, 2026 | Volume: 73 | Issue: 6 | Pages: 1118-1127

10.1002/mus.70230 | PMID 41937511 Get It

ABSTRACT Introduction/Aims Eplontersen is approved in multiple regions for adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‐PN). This exploratory analysis was conducted to evaluate the treatment effect of eplontersen by sex in patients with ATTRv‐PN from the NEURO‐TTRansform trial (NCT04136184). Methods Participants in NEURO‐TTRansform who received ≥ 1 dose of eplontersen were included in this analysis; participants in the inotersen reference group who switched to eplontersen were excluded. Eplontersen was evaluated in the overall patient population and in a subgroup with cardiomyopathy. Change from baseline in the NEURO‐TTRansform primary endpoints of serum transthyretin (TTR) levels to Week 65, modified Neuropathy Impairment Score +7 (mNIS+7) composite score to Week 66, and Norfolk Quality of Life‐Diabetic Neuropathy (Norfolk QoL‐DN) total score to Week 66 were evaluated. A historical placebo group from the NEURO‐TTR trial (NCT01737398) was included as a control. Results The eplontersen group comprised 100 (69.4%) male and 44 (30.6%) female patients. The placebo group comprised 41 (68.3%) male and 19 (31.7%) female patients. For both sexes, treatment with eplontersen decreased serum TTR levels by > 80% (vs. reductions of 3%–13% with placebo), maintained mNIS+7 scores, and improved Norfolk QoL‐DN scores (vs. deterioration with placebo). The treatment effect of eplontersen was similar in male and female patients with cardiomyopathy. Discussion Eplontersen halted neuropathy impairment and improved quality of life versus placebo to a similar degree in both male and female patients with ATTRv‐PN, including those with cardiomyopathy. These findings support the use of eplontersen as an effective treatment for ATTRv‐PN regardless of sex.
Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform
Gillmore, Julian D., Adams, David, Weiler, Markus , Masri, Ahmad, Obici, Laura, Nåtman, Jonatan , Kwoh, T. Jesse, Reicher, Barry , Revkin, James H. , Gertz, Morie, Chao, Chi‐Chao, Gillmore, Julian D. , Adams, David , Gillmore, Julian D , Adams, David , Gertz, Morie A , Masri, Ahmad , Obici, Laura , Waddington‐Cruz, Márcia , Gertz, Morie A. , Chao, Chi‐Chao

Mayo Clinic

European Journal of Neurology | March 31, 2026 | Volume: 33 | Issue: 4 | Pages: No page available

10.1111/ene.70580 | PMID 41913562 Get It

ABSTRACT Background This exploratory analysis of the NEURO‐TTRansform Phase 3 trial evaluated the efficacy of eplontersen in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy by genetic variant. Methods Changes from baseline in NEURO‐TTRansform primary endpoints serum transthyretin (TTR) at Week 65, modified Neuropathy Impairment Score+7 (mNIS+7) composite score, and Norfolk Quality of Life‐Diabetic Neuropathy (Norfolk QoL‐DN) total score at Week 66 were evaluated in patients with early‐onset (aged < 50 years) and late‐onset (aged ≥ 50 years) Val30Met (p.Val50Met) or non‐Val30Met ATTRv amyloidosis with polyneuropathy. Secondary endpoints from NEURO‐TTRansform were also evaluated by genetic variant. Results In total, 144 patients with early‐onset ( n = 54) or late‐onset ( n = 31) Val30Met or non‐Val30Met ( n = 59), ATTRv amyloidosis with polyneuropathy were randomized to eplontersen. A further 60 patients from NEURO‐TTR with early‐onset ( n = 16) or late‐onset ( n = 17) Val30Met or non‐Val30Met ( n = 27), served as a historical placebo group. The mean percentage difference (95% confidence interval) in serum TTR was −79.9 (−87.8, −72.0), −85.0 (−93.3, −76.6), and −70.6 (−77.7, −63.5) with eplontersen versus placebo in the early‐ and late‐onset Val30Met, and non‐Val30Met groups, respectively. Across subgroups, the change from baseline to Week 66 in mNIS+7 composite score was generally well maintained, and the Norfolk QoL‐DN total score improved with eplontersen versus worsening with placebo. The Polyneuropathy Disability score was maintained in most patients. From baseline to Week 65, the modified body mass index was maintained with eplontersen compared to a marked reduction (worsening) for placebo. Conclusions Findings were suggestive of consistent benefits in reducing neuropathy impairment and improving QoL with eplontersen versus historical placebo, across TTR variants. Trial Registration ClinicalTrials.gov: NCT04136184, NCT01737398
Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies
Maron, Barry J. , Ommen, Steven R., Ra, Nishimura, McKenna, William J. , Rakowski, H., Olivotto, I, Braunwald, Eugene, Maron, Martin S., Nishimura, Rick A. , McKenna, William J. , Olivotto, Iacopo , Ommen, Steve R , Nishimura, Rick A , Rakowski, Harry , Sherrid, Mark , Olivotto, Iacopo , Maron, Martin S , Maron, Barry J. , Ommen, Steve R. , Sherrid, Mark V. , Braunwald, Eugene , Maron, Martin S.

Mayo Clinic

Journal of the American Heart Association | March 25, 2026 | Volume: 15 | Issue: 12 | Pages: No page available

10.1161/jaha.125.047462 | PMID 41878858 Get It

Once considered rare and essentially untreatable with a grim prognosis and reduced life expectancy, hypertrophic cardiomyopathy (HCM) has evolved substantially over 6 decades. Ultimately, HCM has become a contemporary global disease with pharmacologic and interventional options offering effective personalized treatment for all adverse disease pathways. Striking reduction in HCM‐related mortality to ≤0.5%/year in optimally treated cohorts is now comparable to that expected in the US general population, lower than most other disease risks to living, and 10‐fold less than the earliest estimates. The few deaths directly related to HCM are now largely attributable to advanced (end‐stage) heart failure in patients with nonobstructive HCM. Determinants of this transformation to a lower risk disease are evident in hallmark clinical inflection points and breakthroughs, including dedicated HCM programs assembling large clinical databases in which focused (and unfunded) physician‐investigators have derived data directly from patients in clinical practice. Evidence‐based observational studies report emergence of contemporary treatment strategies enhancing survival: implantable defibrillators prevent arrhythmic sudden death globally with 95% sensitive patient selection using an American Heart Association/American College Cardiology risk stratification algorithm; low‐risk, high‐benefit surgical myectomy reverses outflow obstruction and heart failure in >90% with a long‐term survival benefit; and aggressive anticoagulation has reduced embolic strokes. Recent novel pharmacologic alternatives (cardiac myosin inhibitors) are proving effective in relieving obstruction/symptom burden and changing disease management. These principles and time‐tested patient‐centered research strategies uniquely tailored to the heterogeneous HCM clinical spectrum are pivotal in providing practice insights, offering a vulnerable population more optimistic prognosis including opportunity to achieve normal longevity not available to prior generations of patients.